Affiliation:
1. CSIR- Central Institute of Medicinal and Aromatic Plants,Molecular Bioprospection Department,Lucknow,India,
2. Central University of South Bihar,Department of Pharmacy,Gaya,India,
3. Pragya College of Pharmaceutical Sciences,Gaya,India,
4. CSIR- Central Institute of Medicinal and Aromatic Plants,Molecular Bioprospection Departmen,ucknow,India,
Abstract
Stomach cancer is a global health challenge due to its increasing prevalence.
The intestinal microbiota of humans plays a vital role in producing short-chain fatty
acids, developing resistance towards pathogenic microbes, nutrient absorption,
modulation in immunological response, metabolism, synthesis of vitamins, and gut
immune system development. Many diseases or disorders, including cancers, obesity,
psychiatric illnesses, rheumatoid arthritis, and inflammatory bowel syndrome, are
associated with an imbalance of microbiotas. Earlier reports suggest that probiotics via
the oral route act as a functional food and suppress cancer development. Further, some
probiotics are clinically effective in reducing post-operative inflammation in cancer
patients. Probiotics primarily display inhibitory effects against H. pylori infections in
the digestive tract. The combination of probiotics with antibiotics has effectively
eradicated H. pylori infections. Besides, probiotics reduce the pro-carcinogens
metabolism, they also diminish the growth of pathogens and improve the consistency
of the intestinal barrier. Moreover, compounds produced by the microorganisms are
reported to interact unswervingly with cancer cells and affect their survival. The
therapeutic efficacy and adverse side-effects of the strategies used for stomach cancer
prevention could be improved by using probiotics either as adjuvant or neo-adjuvant as
the safety concern of the commercially used strains has been verified. The underlying
mechanism describing microbiota's effect on oncogenic activation, carcinogenic
metabolite production, DNA damage, inhibition of tumour immunity, and chronic
inflammation induction still needs a more detailed investigation. In addition, double blind, placebo-controlled, randomized, and well-designed clinical studies are required
to understand the efficacy and mode of action to reduce the death rate and stomach
cancer burden. In depth studies are essential to set probiotics as an eccentric strategy
for stomach cancer prevention and treatment.<br>
Publisher
BENTHAM SCIENCE PUBLISHERS